Articles by Michelle Hoffman - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Michelle Hoffman

Passion, Innovation, and Loss

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.
Nov 2, 2011

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.

Retrospection and Introspection at FDA

A report commissioned by FDA evaluates the QbD program.
Sep 2, 2011

A report commissioned by FDA evaluates the QbD program.

Biosimilars or Bust

Are biosimilars the next big thing or just the next big bubble?
Aug 2, 2011

Are biosimilars the next big thing or just the next big bubble?

Legislation v. Litigation

Which route will we take to arrive at a national stem-cell policy?
Jul 2, 2011

Which route will we take to arrive at a national stem-cell policy?

Perception and Reality

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.
May 2, 2011

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Bioprocessing Trends: Annual Survey

Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.
May 1, 2011

Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.

Celebrity Couples to Disunite

Research and development may be headed for divorce.
Apr 2, 2011

Research and development may be headed for divorce.

Follow-Ons: The New Black?

Follow-ons were all the rage at this year's JP Morgan Healthcare Conference.
Feb 2, 2011

Follow-ons were all the rage at this year's JP Morgan Healthcare Conference.

What a Piece of Work is Pharma

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.
Jan 2, 2011

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here